Table 1 Demographic data and clinical parameters of patients and controls
Variable | TDT patients (n = 55) | Controls (n = 30) | P value |
|---|---|---|---|
Age | 7–19 (8.3 + 4.1) | 8–20 (8.5 + 3.8) | 0.992 |
Height | 105–160 (121.2 ± 11.5) | 114–162 (128.2 ± 10.5) | 0.841 |
Weight | 16–42 (27.53 ± 4.26) | 19–47 (29.59 ± 5.62) | 0.794 |
Duration of the disease (years) | – | – | |
Iron chelation therapy | |||
Deferoxamine monotherapy (SC, IV) | 9 (16.3%) | – | |
Deferasirox monotherapy (Oral) | 21 (38.18%) | ||
Deferiprone monotherapy (Oral) | 17 (30.9%) | ||
Deferoxamine (SC,IV) and deferasirox (Oral) | 8 (14.5%) | ||
Serum ferritin (ng/ml) | 1932–6070 (2721.43 ± 815.17) | – | – |
Hb level (gm/dl) | 7.1–10.4 (8.1 ± 1.3) | – | – |
Serum iron (mcg/dl) | 654–1220 (798.64 ± 271.56) | – | – |